JPMorgan: GDP Growth 'Is Like Running on Red Bull'
*By Michael Teich*
President Trump's top economic advisor Larry Kudlow said this week that economic growth could top [4 percent](https://www.cnbc.com/2018/07/18/trump-advisor-kudlow-says-economic-growth-could-top-4percent-for-a-quarter-.html).
And while JPMorgan ETFs global market strategist Samantha Azzarello agrees, she does doubt its sustainability.
"It’s like running on Red Bull, which you can not do forever," she told Cheddar in an interview Thursday.
The economy is getting a jolt from tax cuts, government spending, and high consumption. But trade tensions have weighed on the markets recently, and as Azzarello explained, we're late in the cycleーthe bull market turned 9 years old in March, its longest ever run.
"There's fatigue with this bull market, which is bizarre. We should feel good that the earnings growth is so good," she said.
"If you contrast the earnings data, which is so positive and so strong, with how much the market is up, it literally doesn't make any sense."
For the full segment, [click here.](https://cheddar.com/videos/u-s-economy-running-on-red-bull-but-wont-last-says-market-strategist)
Co-founder and CEO of Colossal Ben Lamm explains how the company is working to bring back extinct species and shares early details of the upcoming documentary from the ‘My Octopus Teacher’ filmmaker.
Soundhound AI co-founder, president, and CEO Keyvan Mojaver discusses bringing its audio tools to cars and drive-thrus, plus why smaller companies may benefit from the A.I. boom.
Deiya Pernas, co-founder of Pernas Research, breaks down Nvidia’s blockbuster earnings, why energy is a sector to watch, and why the A.I. trend is far from over.
The NBA is organizing its next media rights deal to figure out which networks and streaming services will show their games for the next decade. Last time, most of the prominent streaming services didn't exist yet.
Jessica Traver Ingram, CEO and co-founder of IntuiTap Medical, discusses developing the company's Ver Touch device, the crucial FDA approval it just won, and why innovation in spinal blocks and epidurals is long overdue.
